Omega-3 Fish Oil, EPA, DHA, and Inflammation: REDUCE-IT Trial, Triglyceride Reduction, Rancidity, and Dosing by Goal

Updated: June 2026omega-3 fish oil · EPA DHA inflammation · fish oil triglycerides · REDUCE-IT trial omega-3 · best fish oil supplement · omega-3 vs omega-6 · EPA vs DHA difference · fish oil rancidity TOTOX · omega-3 cardiovascular · algal oil vegan omega-3 · omega-3 depression · omega-3 index · fish oil dosage · krill oil vs fish oil · omega-3 triglyceride form · fish oil anti-inflammatory · ALA conversion EPA DHA · fish oil CoA quality

Fish oil is one of the most purchased supplements globally — and one of the most quality-variable. The active compounds, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), have robust evidence for reducing triglycerides, evidence for cardiovascular benefit at high doses, emerging evidence in depression and cognitive function, and clear roles in resolving inflammatory signaling. The supplement aisle problem is that the dose needed for these effects (2–4g EPA+DHA per day) is rarely achieved by standard "1000mg fish oil" capsules, which typically contain 300mg EPA+DHA per capsule — requiring 7–14 capsules for therapeutic dosing. Understanding the distinction between total fish oil dose and EPA+DHA content is the first correction most people need to make.

The second correction is quality. Fish oil is a highly oxidizable lipid, and a significant proportion of commercial fish oil products are rancid at the time of sale — with TOTOX scores (total oxidation, measured as peroxide value × 2 + anisidine value) exceeding the 26-point threshold recommended by the Global Organization for EPA and DHA Omega-3s (GOED). A 2015 study (Albert 2015, Journal of Nutritional Science) tested 171 New Zealand fish oil products and found 83% exceeded international oxidation standards at some point during the product's shelf life. Consuming oxidized fish oil is not just ineffective — oxidized lipids may be pro-inflammatory.

20–30%
triglyceride reduction at 4g/day EPA+DHA — FDA-approved prescription-strength omega-3s (Vascepa/icosapentaenoic acid, Lovaza/EPA+DHA) are indicated for severe hypertriglyceridemia (≥500 mg/dL) at 4g/day; mechanism: reduces hepatic VLDL-TG synthesis by inhibiting DGAT1/2 enzymes; increases TG clearance via lipoprotein lipase upregulation; at 1–2g/day (achievable with standard supplementation): ~10–15% reduction; dose-response is steep — 4g/day produces substantially greater effect than 2g; this is why achieving therapeutic triglyceride reduction requires concentrated omega-3 products, not standard 1000mg softgels
25%
MACE reduction in REDUCE-IT — Bhatt 2019 (NEJM, N=8,179): icosapentaenoic acid (pure EPA, Vascepa) 4g/day vs mineral oil placebo in statin-treated patients with TG 135–499 mg/dL + established CV disease or T2DM; primary endpoint: MACE (CV death, MI, stroke, angina hospitalization, revascularization); 25% relative risk reduction over 4.9 years; absolute risk reduction 4.8%; NNT approximately 21; note: mineral oil comparator raised LDL-C and CRP in control group — may have made EPA look better than it would vs true placebo; STRENGTH trial (EPA+DHA vs corn oil comparator): no significant CV benefit — the pure EPA vs EPA+DHA distinction and comparator choice remain debated
<0.05%
ALA→DHA conversion — alpha-linolenic acid (ALA, from flaxseed, chia, walnuts, hemp) is the plant-based omega-3 precursor; conversion to EPA via elongation/desaturation enzymes: 0.2–8%; conversion to DHA: <0.05% in most adults; women of reproductive age convert slightly more (estrogen upregulates the FADS enzymes involved); vegans relying on ALA sources have systematically lower EPA and DHA blood levels; the solution: algal oil (derived from microalgae — the same source fish accumulate DHA from); algal oil provides EPA and DHA without fish; same bioavailability as fish oil; appropriate for vegans/vegetarians
TOTOX
<26
rancidity standard — TOTOX = peroxide value (PV) × 2 + anisidine value (AV); GOED standard: PV <5 meq/kg, AV <20, TOTOX <26; how to check: ask the brand for a Certificate of Analysis (COA) from a third-party lab; reputable brands post COAs on their website; if the brand won't provide a COA, do not buy; sensory test: fresh fish oil should taste faintly of the ocean, not fishily unpleasant; burping fishy after fish oil capsules = likely rancid oil; freeze capsules to reduce burping AND slow oxidation; refrigerate after opening
Want the full evidence writeup?
The Stack Protocol builds four complete goal stacks — Energy, Focus, Sleep, Longevity — with exact doses, timing, budget tiers, and a 30-day rollout plan, graded with the same evidence framework behind this page.
Get the Stack Protocol → $19

EPA vs DHA: Different Functions, Different Targets

PropertyEPA (20:5n-3)DHA (22:6n-3)
Primary locationPlasma phospholipids, plateletsBrain, retina, sperm (30–40% of brain PUFA)
Anti-inflammatory mechanismResolvin E series; competes with AA for COX-2; reduces LTB4Resolvin D series; neuroprotectins; reduces neuroinflammation
CardiovascularPrimary — REDUCE-IT evidence; reduces TG, fibrinogen, platelet aggregationSecondary; also reduces TG but less CV trial evidence for EPA dose
Depression/moodPrimary antidepressant signal — Liao 2019 meta-analysis: EPA >60% of doseWeak antidepressant signal alone; synergistic with EPA
Brain developmentMinor roleCritical — DHA is required for synaptic membrane fluidity, neuronal migration
PregnancyStandard supplementation200–300mg DHA/day recommended during pregnancy for fetal brain/retina
Dosing Protocol by Goal

General anti-inflammatory / maintenance: 1–2g combined EPA+DHA per day; read the label — a "1000mg fish oil" capsule typically contains 180mg EPA + 120mg DHA = 300mg active; need 3–7 standard capsules OR 1–2 concentrated-form capsules; take with the largest meal of the day (fat increases absorption of ethyl ester form by 35%).

Triglyceride reduction: 3–4g EPA+DHA per day; requires prescription (Vascepa, Lovaza) or high-potency concentrated supplement; at this dose: expect 20–30% TG reduction in 6–8 weeks; recheck lipid panel at 8 weeks; may mildly increase LDL-C in some patients (DHA effect more than EPA).

Depression (adjunctive): 1–2g EPA per day, with EPA comprising >60% of total omega-3 dose; pure EPA formulas (Vascepa, or supplements listing EPA-dominant content) are preferred over DHA-dominant or balanced formulas; 4–8 weeks to observe mood effect; most evidence as adjunct to antidepressants, not monotherapy.

Quality selection checklist: Choose triglyceride form (natural oil) or re-esterified triglyceride form over ethyl ester for best absorption without food requirement; verify TOTOX <26 on COA; IFOS or NSF certified preferred; store refrigerated after opening; discard if fishiness develops; molecular distillation removes heavy metals — verify on COA.

Safety notes: At 4g/day: mild increase in bleeding time (clinically significant primarily if on anticoagulants like warfarin or direct oral anticoagulants — discuss with prescriber); may lower blood pressure slightly (beneficial in most contexts); safe in pregnancy at standard doses (DHA is beneficial); very rare risk of AF at very high doses per REDUCE-IT secondary analysis.

High-Potency Fish Oil (TG Form) → Algal Oil (Vegan) →

Related supplement guides

Magnesium Forms → Vitamin K2 → Iron Absorption → Rhodiola Rosea →

As an Amazon Associate, StackProtocol earns from qualifying purchases made through links on this page. This does not affect the price you pay.